Neuphoria Therapeutics (NEUP) Exchange Rate Effect (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Exchange Rate Effect of $527059.0 for Q1 2026, up 520.3% year-over-year from $84969.0 in Q1 2025, and up 78.42% on a QoQ basis from $295406.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Exchange Rate Effect data on file, last reported at $527059.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 520.3% year-over-year to $527059.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $852616.0 (up 4384.86% YoY) and the FY2025 annual result came in at -$3750.0, down 104.87% from the prior year.
- Exchange Rate Effect grew to $527059.0 in Q1 2026 per NEUP's latest filing, from $295406.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $527059.0 in Q1 2026 and bottomed at -$276692.0 in Q4 2024.
- The 4-year median for Exchange Rate Effect is $72367.0 (2024), against an average of $79657.6.
- The widest annual swing landed in 2024, when Exchange Rate Effect sank 180.61%; it then surged 520.3% in 2026.
- Tracing NEUP's Exchange Rate Effect over 4 years: stood at $343242.0 in 2023, then slumped by 180.61% to -$276692.0 in 2024, then jumped by 206.76% to $295406.0 in 2025, then soared by 78.42% to $527059.0 in 2026.
- Per Business Quant, the three latest NEUP Exchange Rate Effect figures stand at $527059.0 (Q1 2026), $295406.0 (Q4 2025), and -$19455.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.60 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -2.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -40.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -900,000.00 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -7.06 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 527,059.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 527,059.00 |
| Mar 31, 2026 | 527,059.00 |
| Dec 31, 2025 | 295,406.00 |
| Dec 31, 2025 | 295,406.00 |
| Sep 30, 2025 | -19,455.00 |
| Sep 30, 2025 | -19,455.00 |
| Jun 30, 2025 | 49,606.00 |
| Jun 30, 2025 | 49,606.00 |
| Mar 31, 2025 | 84,969.00 |
| Mar 31, 2025 | 84,969.00 |
| Dec 31, 2024 | -276,692.00 |
| Dec 31, 2024 | -276,692.00 |
| Sep 30, 2024 | 138,367.00 |
| Sep 30, 2024 | 138,367.00 |
| Jun 30, 2024 | 72,367.00 |
| Jun 30, 2024 | 72,367.00 |
| Mar 31, 2024 | -185,862.00 |
| Mar 31, 2024 | -185,862.00 |
| Dec 31, 2023 | 343,242.00 |
| Dec 31, 2023 | 343,242.00 |
| Sep 30, 2023 | -152,773.00 |
| Sep 30, 2023 | -152,773.00 |